|
Compound class:
Synthetic organic
Comment: Carmoterol was investigated as an ultra-long-acting β-adrenoreceptor agonist, but clinical development was terminated.
Interactions with this ligand were removed during a general review of the adrenoceptors family that was completed in September 2026. There is no additional information about this ligand in the Guide to PHARMACOLOGY. |
|
|||||||||||||||||||||||||||||||||||